Improving access to care in low and middle-income countries: Institutional factors related to enrollment and patient outcome in a cancer drug access program

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Tekinturhan, Ebru ^a   Audureau, Etienne ^b   Tavolacci, Marie Pierre ^c   Garcia Gonzalez, Patricia ^d   Ladner, Joël ^c   Saba, Joseph ^a  

^a Axios International   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d Max Foundation   (United States)

Author keywords

Access to medication; Cancer; Enrollment; Implementation; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; DEVELOPING COUNTRY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE DELIVERY; HUMAN; MALE; MIDDLE AGED; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; SURVIVAL; TOTAL QUALITY MANAGEMENT;

ANTINEOPLASTIC AGENTS; BENZAMIDES; DEVELOPING COUNTRIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PYRIMIDINES; QUALITY IMPROVEMENT; SURVIVAL;

EID: 84881180951     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-304     Document Type: Article

References (29)

1. Expansion of cancer care and control in countries of low and middle income: a call to action. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, et al. Lancet 2010 376 9747 1186 1193 10.1016/S0140-6736(10)61152-X 20709386
2. Decreasing the cancer burden in developing countries: concerns and recommendations. Kachroo S, Etzel CJ, Eur J Cancer Care 2009 18 1 18 21 10.1111/j.1365-2354.2008.00985.x
3. Population causes and consequences of leading chronic diseases: a comparative analysis of prevailing explanations. Stuckler D, Milbank Q 2008 86 2 273 326 10.1111/j.1468-0009.2008.00522.x 18522614
4. The rising burden of cancer in the developing world. Kanavos P, Ann Oncol 2006 17 Suppl 8 &22iii15 viii23 16801335
5. Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic? CanTreat International, Ann Oncol 2010 21 4 680 682 20338877
6. The roles of national cancer research institutions in evolving a comprehensive cancer control program in a developing country: experience from Uganda. Orem J, Wabinga H, Oncology 2009 77 5 272 280 10.1159/000259258 19923865
7. Progress in public-private partnerships to fight neglected diseases. Gustavsen K, Hanson C, Health Aff 2009 28 6 1745 1749 10.1377/hlthaff.28.6.1745
8. The case of ivermectin: lessons and implications for improving access to care and treatment in developing countries. Sturchio JL, Community Eye Health 2001 14 38 22 23 17491909
9. Chirac P, Increasing the access to antiretrovial drugs to moderate the impacts of AIDS: an exploration of alternative options. AIDS, Public Policy and Child Well-being 2002 Chapter 14
10. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. Wertheimer AI, Santella TM, Lauver HJ, J Int Assoc Physicians AIDS Care (Chic) 2004 3 3 74 79 84-75 10.1177/ 154510970400300302
11. Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP. Kanavos P, Vandoros S, Garcia-Gonzalez P, Glob Heal 2009 5 19 10.1186/1744-8603-5-19
12. Cancer initiatives in developing countries. Mellstedt H, Ann Oncol 2006 17 Suppl 8 & 22iii24 viii31 16801336
13. Cancer in developing countries: challenges and solutions. Reeler AV, Mellstedt H, Ann Oncol 2006 17 Suppl 8 & 22iii7 viii8 16801341
14. Cervical cancer screening programs in low-income communities. Experiences from Ecuador. Low cost detection of HPV infection in a developing country. Cecchini G, Paganini G, D'Amico M, Cannone M, Bertuletti C, Barberis MC, Pathologica 2009 101 2 76 79 19886552
15. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Sepulveda C, Prado R, Cancer Detect Prev 2005 29 5 405 411 10.1016/j.cdp.2005.07.001 16188399
16. Complex care systems in developing countries: breast cancer patient navigation in Ethiopia. Dye TD, Bogale S, Hobden C, Tilahun Y, Hechter V, Deressa T, Bize M, Reeler A, Cancer 2010 116 3 577 585 10.1002/cncr.24776 20029968
17. Indications for imatinib mesylate therapy and clinical management. Guilhot F, Oncologist 2004 9 3 271 281 10.1634/theoncologist.9-3-271 15169982
18. Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. Corm S, Micol J, Leroyer A, Daudignon A, Preudhomme C, Poulain S, Bregman B, Oukessou A, Lai J, Facon T, J Clin Oncol 2008 26 15S (May 20 Supplement) 7088 Abstract
19. Epidemiology of chronic myeloid leukaemia (CML). Rohrbacher M, Hasford J, Best Pract Res Clin Haematol 2009 22 3 295 302 10.1016/j.beha.2009.07.007 19959081
20. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, et al. Blood 2008 111 3 1039 1043 17932248
21. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, et al. Leukemia 2009 23 6 1054 1061 10.1038/leu.2009.38 19282833
22. Ongoing challenges of a global international patient assistance program. Lassarat S, Jootar S, Ann Oncol 2006 17 Suppl 8 & 22iii43 viii46 16801339
23. The GLIVEC international patient assistance programme: the Nairobi experience. Kiarie GW, Othieno-Abinya NA, Riyat MS, East Afr Med J 2009 86 12 Suppl 106 S107 21591520
24. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, et al. Lancet Oncol 2011 12 9 841 851 10.1016/S1470-2045(11)70201-7 21856226
25. Clinical experience to date with nilotinib in gastrointestinal stromal tumors. Reichardt P, Montemurro M, Semin Oncol 2011 38 Suppl 1 20 S27 21419932
26. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Italiano A, Cioffi A, Coco P, Maki RG, Schoffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Ann Surg Oncol 2011 71 5 1551 1559
27. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M, Schoffski P, Reichardt P, Gelderblom H, Schutte J, Hartmann JT, Von Moos R, Seddon B, Joensuu H, Wendtner CM, et al. Eur J Cancer 2009 45 13 2293 2297 10.1016/j.ejca.2009.04.030 19467857
28. Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase. Garnock-Jones KP, Drugs 2011 71 12 1579 1590 10.2165/11207770-000000000-00000 21861543
29. Projections of global mortality and burden of disease from 2002 to 2030. Mathers CD, Loncar D, PLoS Med 2006 3 11 442 10.1371/journal.pmed.0030442 17132052